Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 1

4(80.0%)

Phase 2

1(20.0%)

5Total

Phase 1(4)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07277582Phase 2Recruiting

Evaluation of Efficacy and Safety of THRV-1268 in Long QT Syndrome Type 2 (LQTS 2)

Role: lead

NCT07186946Phase 1Completed

Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, PK, PD, and Comparative Bioavailability of THRV-1268 in Obese Adult Participants

Role: lead

NCT07075445Recruiting

Observational Study to Describe Health-Related Quality of Life and Measure Disease Burden Among Patients With Long QT Syndrome Types (LQTS) 2 and 3

Role: lead

NCT05906732Phase 1Terminated

Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2).

Role: lead

NCT06507839Phase 1Completed

Study to Assess the Safety, Tolerability, Pharmacokinetic of Thrv-1268

Role: lead

NCT05759962Phase 1Completed

Phase 1 Study of LQT-1213 in Healthy Adults

Role: lead

All 6 trials loaded